ReviewBiotechnologia2024
Quercetin nanoparticles as a therapeutic approach: pharmacological actions and potential applications in therapy.
Review in Biotechnologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Quercetin-Based Nanotherapeutics for Targeted Drug Delivery in Alzheimer's Disease: Comparative Insights into Molecular Mechanisms, Blood-Brain Barrier Targeting and Therapeutic Perspectives.Molecular neurobiology · 2026Review
- Quercetin as a multi-targeted therapeutic candidate in oral cancers: molecular mechanisms and preclinical evidence.Molecular biology reports · 2026Review
- Cytoprotective and Genoprotective Effects of Gelatin-Encapsulated Quercetin Against Oxidative Cell Damage.Molecules (Basel, Switzerland) · 2026Article
- Quercetin and nanoquercetin mitigate high fat diet-induced obesity via lipid modulation, genomic DNA integrity restoration, adipokine regulation, and hepato-pancreatic tissue preservation.Scientific reports · 2026Article
- Review
- Exploring the Interplay of Antioxidants, Inflammation, and Oxidative Stress: Mechanisms, Therapeutic Potential, and Clinical Implications.Diseases (Basel, Switzerland) · 2025Review
- Quercetin as an Anti-Diabetic Agent in Rodents-Is It Worth Testing in Humans?International journal of molecular sciences · 2025Review
- Bibliometric Mapping of Quercetin Research: Analysis of the Most-Cited Articles (2000-2023).Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The utilization of quercetin nanoparticles as a novel therapeutic strategy has garnered significant attention in recent years. These nanoparticles offer a unique approach to enhancing delivery and effectiveness while overcoming the drawbacks of quercetin. By exploiting the advantages of nanotechnology, such as increased stability and improved bioavailability, quercetin nanoparticles hold significant potential for developing innovative treatments across various medical fields. Quercetin nanoparticles have emerged as an indispensable component in numerous pharmaceutical and medicinal formulations. They are recognized for their anticancer, antitumor, anti-inflammatory, and antidiabetic properties, making them valuable in addressing allergic reactions, metabolic disorders, inflammatory disorders, cardiovascular diseases, and arthritis. From a pharmacological perspective, quercetin nanoparticles have demonstrated beneficial effects against Alzheimer's disease, primarily through their inhibitory impact on acetylcholinesterase. Furthermore, these nanoparticles have been scientifically documented to possess antioxidant, anticarcinogenic, hepatoprotective, and cytotoxic activities. This comprehensive review aims to explore the pharmacokinetics and biological activities associated with quercetin nanoparticles. It also highlights their potential as therapeutic agents in treating a wide range of diseases, including Alzheimer's disease, cancer, and neurodegenerative disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.